Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800, Villejuif, France; LabEx LERMIT, Université Paris Saclay, 92296 Châtenay-Malabry, France; Inovarion, 75005 Paris, France.
Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, 94800, Villejuif, France; LabEx LERMIT, Université Paris Saclay, 92296 Châtenay-Malabry, France.
Trends Mol Med. 2021 Feb;27(2):138-151. doi: 10.1016/j.molmed.2020.09.007. Epub 2020 Oct 9.
Taxanes are microtubule-targeting drugs used as cytotoxic chemotherapy to treat most solid tumors. The development of resistance to taxanes is a major cause of therapeutic failure and overcoming chemoresistance remains an important challenge to improve patient's outcome. Extensive efforts have been made recently to identify predictive biomarkers to select populations of patients who will benefit from taxane-based chemotherapy and avoid inefficient treatment of patients with innate resistance. This, together with the discovery of new mechanisms of resistance that include metabolic reprogramming and dialogue between tumor and its microenvironment, pave the way to a new era of personalized medicine. In this review, we recapitulate recent insights into taxane resistance and present promising emerging strategies to overcome chemoresistance in the future.
紫杉烷类药物是微管靶向药物，用作细胞毒化疗药物来治疗大多数实体瘤。对紫杉烷类药物的耐药性的发展是治疗失败的主要原因，克服化疗耐药性仍然是提高患者疗效的重要挑战。最近，人们已经做出了大量努力来识别预测性生物标志物，以选择受益于基于紫杉烷类的化疗的患者群体，并避免对具有固有耐药性的患者进行无效治疗。这一点，再加上对耐药新机制的发现，包括代谢重编程和肿瘤与其微环境之间的对话，为个性化医疗的新时代铺平了道路。在这篇综述中，我们总结了最近对紫杉烷类耐药性的认识，并提出了有前途的新兴策略，以克服未来的化疗耐药性。
